Two new studies offer insights into the molecular biology of neuropsychiatric disease

FHS
May 24, 2024
5:11 pm

Working under the umbrella of the PsychENCODE Consortium, the mental health research project established in 2015 by the National Institutes of Health, a team of Mount Sinai scientists has uncovered important new insights into the molecular biology of neuropsychiatric disease through two new studies published in a special issue of Science on Friday, May 24.

Meta Title: “Forma Therapeutics Inc Files Patent for USP30 Inhibitor Compounds

Share this article According to GlobalData’s company profile on Forma Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Forma Therapeutics‘s grant

April 1, 2024

Key viral protein produced by influenza A can shred a host cell’s genetic materials, finds study

Influenza A is one of two influenza viruses that fuel costly annual flu seasons and is a near constant threat to humans and many other

June 23, 2023

AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults – Pharmaceutical Technology

On November 16, during the American Heart Association (AHA) 2024 Annual Scientific Sessions in Chicago, IL, US, findings from the Phase III PALISADE (NCT05089084) clinical

November 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.